However, KRAS mutation is less common in the setting of MSI [111], and as was demonstrated in the Keynote-164 trial, KRAS-mutated MSI cancers confer a lower objective response compared to KRAS-wildtype cancers [110]. Here, KRAS is linked to cancer.